Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
- CASPIAN investigators
- University of California at Los Angeles
- BHI of Omsk Region Clinical Oncology Dispensary
- State Institution of Healthcare
- Cancer and Hematology Centers of Western Michigan
- Asklepios Lung Clinic
- Okayama University
- Odessa Regional Oncological Dispensary
- Omsk Regional Cancer Centre
- Klinik Floridsdorf
- Istanbul University - Cerrahpaşa
- Samsung Changwon Hospital
- IRCCS Fondazione Istituto Nazionale per lo studio e la cura dei tumori - Milano
- Kyiv City Clinical Oncological Centre
- Russian Ministry of Health
- FSI "SRC of Oncology n. a. N.N. Petrov of Rosmedtekhnologiy"
- Hospital Universitario 12 de Octubre
- AO Ospedali Riuniti PO Vincenzo Cervello
- Charles University
- Zaporizhia Medical Academy of Post-Gradate Education Ministry of Health of Ukraine
- MI Dnipropetrovsk City Multi-Field Clinical Hospital #4
- Tuberculosis and Lung Disease Hospital
- Samodzielny Publiczny Zespół Gruźlicy i Chorób Płuc
- Semmelweis University
- University Hospital St. Marina
- AstraZeneca
Research output: Contribution to journal › Article › peer-review
628
Link opens in a new tab
Scopus
citations